Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Truqap Plus Faslodex Approved in the EU for Patients with Advanced ER-Positive Breast Cancer

[AstraZeneca] AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with ER-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis

[Science] Scientists applied a combination of intravital and ex vivo three-dimensional confocal microscopy, micro–computed tomography, and histologic analyses to mouse models of bone-metastatic breast cancer and leptomeninges (LM) metastasis,. They demonstrated that breast cancer cells could traffic to the LM from the bone marrow through abluminal emissary vein migration.

Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer

[Cancer Research] The authors applied a mass spectrometry-based proteomic approach to characterize human serum extracellular vesicles (EV) derived from patients with breast cancer (BC). TALDO1 was found to be an EV biomarker of distant metastasis of BC. In vitro and in vivo analysis confirmed the role of TALDO1 in stimulating BC invasion and metastasis.

QL1209 (Pertuzumab Biosimilar) versus Reference Pertuzumab plus Trastuzumab and Docetaxel in Neoadjuvant Treatment for HER2-Positive, ER/PR-Negative, Early or Locally Advanced Breast Cancer: A Multicenter,...

[British Journal of Cancer] This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuzumab biosimilar QL1209 to the pertuzumab (Perjeta®) each with trastuzumab and docetaxel in neoadjuvant treatment of early or locally advanced breast cancer patients with HER2-positive, ER/PR-negative.

Obesity Induces Temporally Regulated Alterations in the Extracellular Matrix That Drive Breast Tumor Invasion and Metastasis

[Cancer Research] To characterize the temporal effects of age and high-fat diet-driven weight gain on the ECM, the authors injected allograft tumor cells at four-week intervals into mammary fat pads of mice fed a control or high-fat diet, assessing tumor growth and metastasis and evaluating the ECM composition of the mammary fat pads, lungs, and livers.

Low BCL-XL Expression in Triple-Negative Breast Cancer Cells Favors Chemotherapy Efficacy, and this Effect is Limited by Cancer-Associated Fibroblasts

[Scientific Reports] Using gene editing or BH3 mimetics to inhibit anti-apoptotic BCL-2 family proteins in TNBC line MDA-MB-231, investigators showed that BCL-xL and MCL-1 promoted cancer cell survival through compensatory mechanisms. This cell line showed limited sensitivity to chemotherapy, in line with the clinical resistance observed in TNBC patients.

Hypoxia-Induced CTCF Promotes EMT in Breast Cancer

[Cell Reports] Researchers showed that hypoxia modulated the epigenetic landscape on CTCF promoter and upregulated its expression. They also uncovered the pivotal role of CTCF in promoting epithelial-mesenchymal transition (EMT) as loss of CTCF abrogated invasiveness of hypoxic breast cancer cells.

Emerging Treatments in HER2-Positive Advanced Breast Cancer: Keep Raising the Bar

[Cell Reports Medicine] The authors describe the evolving treatment landscape of HER2-positive breast cancer, from the current approved therapies to the future perspectives, with a focus on the new agents which are likely to get approved in the next future.

Progressive Senescence Programs Induce Intrinsic Vulnerability to Aging-Related Female Breast Cancer

[Nature Communications] Investigators found that the mammary aging process was asynchronous and progressive, initiated by an early senescence program, succeeded by an entropic late senescence program with elevated cancer associated pathways, vulnerable to cancer predisposition.

Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute

[Xylyx Bio, Inc. (BioSpace)] Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Cancer Institute of the National Institutes of Health (NIH) to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

DUSP6 Inhibition Overcomes Neuregulin/HER3-Driven Therapy Tolerance in HER2+ Breast Cancer

[EMBO Molecular Medicine] Investigators presented transcriptional profiling of HER2+ breast cancer cells transitioning from dormant drug tolerant cells to re-proliferating cells under continuous HER2 inhibitor therapy. Expression of dual-specificity phosphatase DUSP6 was found inhibited in dormant cells, but strongly induced upon regrowth.

Targeting LINC00152 Activates cAMP/Ca2+/Ferroptosis Axis and Overcomes Tamoxifen Resistance in ER+ Breast Cancer

[Cell Death & Disease] Researchers identified LINC00152 inhibition as a novel mechanism of tamoxifen sensitization via restoring tamoxifen-dependent ferroptosis upon destabilizing phosphodiesterase 4D, increasing cAMP and Ca2+ levels, thus leading to reactive oxygen species generation and lipid peroxidation.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.